Collectively, our results highlight the oncogenic role of USP37 in PAAD and suggest that targeting the USP37 pathway could serve as a potential therapeutic approach to suppress tumor growth and improve immune responses in pancreatic cancer. Here, USP37 is linked to pancreatic adenocarcinoma.